MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2

Peilong Li(Shandong University), Chuanxin Wang(Jilin University)
Molecular Cancer Therapeutics
January 9, 2017
Cited by 249


Related Papers